vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and IMAX CORP (IMAX). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $125.2M, roughly 1.4× IMAX CORP). IMAX CORP runs the higher net margin — 0.5% vs -0.7%, a 1.2% gap on every dollar of revenue. On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 0.7%). IMAX CORP produced more free cash flow last quarter ($28.0M vs $21.3M). Over the past eight quarters, IMAX CORP's revenue compounded faster (25.8% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
AVNS vs IMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $125.2M |
| Net Profit | $-1.3M | $637.0K |
| Gross Margin | 47.5% | 57.6% |
| Operating Margin | 1.4% | 19.3% |
| Net Margin | -0.7% | 0.5% |
| Revenue YoY | 0.7% | 35.1% |
| Net Profit YoY | 99.7% | -88.0% |
| EPS (diluted) | $-0.02 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $125.2M | ||
| Q3 25 | $177.8M | $106.7M | ||
| Q2 25 | $175.0M | $91.7M | ||
| Q1 25 | $167.5M | $86.7M | ||
| Q4 24 | $179.6M | $92.7M | ||
| Q3 24 | $170.4M | $91.5M | ||
| Q2 24 | $171.7M | $89.0M | ||
| Q1 24 | $166.1M | $79.1M |
| Q4 25 | $-1.3M | $637.0K | ||
| Q3 25 | $-1.4M | $20.7M | ||
| Q2 25 | $-76.8M | $11.3M | ||
| Q1 25 | $6.6M | $2.3M | ||
| Q4 24 | $-397.3M | $5.3M | ||
| Q3 24 | $4.3M | $13.9M | ||
| Q2 24 | $1.8M | $3.6M | ||
| Q1 24 | $-900.0K | $3.3M |
| Q4 25 | 47.5% | 57.6% | ||
| Q3 25 | 48.4% | 63.1% | ||
| Q2 25 | 52.6% | 58.5% | ||
| Q1 25 | 53.6% | 61.4% | ||
| Q4 24 | 54.6% | 52.2% | ||
| Q3 24 | 54.5% | 55.8% | ||
| Q2 24 | 55.7% | 49.4% | ||
| Q1 24 | 57.1% | 59.3% |
| Q4 25 | 1.4% | 19.3% | ||
| Q3 25 | 0.1% | 27.2% | ||
| Q2 25 | -42.6% | 15.6% | ||
| Q1 25 | 6.1% | 19.3% | ||
| Q4 24 | -233.0% | 10.3% | ||
| Q3 24 | 7.0% | 21.2% | ||
| Q2 24 | 3.7% | 3.2% | ||
| Q1 24 | 2.4% | 15.3% |
| Q4 25 | -0.7% | 0.5% | ||
| Q3 25 | -0.8% | 19.4% | ||
| Q2 25 | -43.9% | 12.3% | ||
| Q1 25 | 3.9% | 2.7% | ||
| Q4 24 | -221.2% | 5.7% | ||
| Q3 24 | 2.5% | 15.2% | ||
| Q2 24 | 1.0% | 4.0% | ||
| Q1 24 | -0.5% | 4.1% |
| Q4 25 | $-0.02 | $0.02 | ||
| Q3 25 | $-0.03 | $0.37 | ||
| Q2 25 | $-1.66 | $0.20 | ||
| Q1 25 | $0.14 | $0.04 | ||
| Q4 24 | $-8.64 | $0.09 | ||
| Q3 24 | $0.09 | $0.26 | ||
| Q2 24 | $0.04 | $0.07 | ||
| Q1 24 | $-0.02 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $151.2M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $337.9M |
| Total Assets | $1.1B | $894.0M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $151.2M | ||
| Q3 25 | $70.5M | $143.1M | ||
| Q2 25 | $90.3M | $109.3M | ||
| Q1 25 | $97.0M | $97.1M | ||
| Q4 24 | $107.7M | $100.6M | ||
| Q3 24 | $89.0M | $104.5M | ||
| Q2 24 | $92.2M | $91.6M | ||
| Q1 24 | $75.8M | $81.0M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $337.9M | ||
| Q3 25 | $778.0M | $349.5M | ||
| Q2 25 | $776.3M | $320.4M | ||
| Q1 25 | $839.4M | $299.5M | ||
| Q4 24 | $828.5M | $299.5M | ||
| Q3 24 | $1.2B | $289.4M | ||
| Q2 24 | $1.2B | $267.2M | ||
| Q1 24 | $1.2B | $258.8M |
| Q4 25 | $1.1B | $894.0M | ||
| Q3 25 | $1.1B | $889.6M | ||
| Q2 25 | $1.0B | $868.6M | ||
| Q1 25 | $1.1B | $848.3M | ||
| Q4 24 | $1.2B | $830.4M | ||
| Q3 24 | $1.7B | $847.6M | ||
| Q2 24 | $1.7B | $827.4M | ||
| Q1 24 | $1.7B | $824.1M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $29.4M |
| Free Cash FlowOCF − Capex | $21.3M | $28.0M |
| FCF MarginFCF / Revenue | 11.8% | 22.3% |
| Capex IntensityCapex / Revenue | 3.8% | 1.1% |
| Cash ConversionOCF / Net Profit | — | 46.11× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $118.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $29.4M | ||
| Q3 25 | $14.0M | $67.5M | ||
| Q2 25 | $6.8M | $23.2M | ||
| Q1 25 | $25.7M | $7.0M | ||
| Q4 24 | $57.9M | $11.5M | ||
| Q3 24 | $23.0M | $35.3M | ||
| Q2 24 | $27.8M | $35.0M | ||
| Q1 24 | $-8.0M | $-11.0M |
| Q4 25 | $21.3M | $28.0M | ||
| Q3 25 | $7.0M | $64.8M | ||
| Q2 25 | $-4.2M | $20.9M | ||
| Q1 25 | $19.0M | $5.3M | ||
| Q4 24 | $53.1M | $6.9M | ||
| Q3 24 | $20.0M | $34.2M | ||
| Q2 24 | $21.9M | $33.5M | ||
| Q1 24 | $-12.1M | $-12.1M |
| Q4 25 | 11.8% | 22.3% | ||
| Q3 25 | 3.9% | 60.7% | ||
| Q2 25 | -2.4% | 22.8% | ||
| Q1 25 | 11.3% | 6.1% | ||
| Q4 24 | 29.6% | 7.4% | ||
| Q3 24 | 11.7% | 37.3% | ||
| Q2 24 | 12.8% | 37.6% | ||
| Q1 24 | -7.3% | -15.3% |
| Q4 25 | 3.8% | 1.1% | ||
| Q3 25 | 3.9% | 2.6% | ||
| Q2 25 | 6.3% | 2.6% | ||
| Q1 25 | 4.0% | 1.9% | ||
| Q4 24 | 2.7% | 5.0% | ||
| Q3 24 | 1.8% | 1.2% | ||
| Q2 24 | 3.4% | 1.8% | ||
| Q1 24 | 2.5% | 1.4% |
| Q4 25 | — | 46.11× | ||
| Q3 25 | — | 3.27× | ||
| Q2 25 | — | 2.06× | ||
| Q1 25 | 3.89× | 2.99× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | 5.35× | 2.54× | ||
| Q2 24 | 15.44× | 9.78× | ||
| Q1 24 | — | -3.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
